Daniela V. Castro

280 posts

Daniela V. Castro

Daniela V. Castro

@DVCastro_

CRA @CityofHope | Aspiring Physician | Interested in GU Oncology | MS @UCSanDiego | #HealthEquity | #TeamPal | Tweets are my own.

Los Angeles, CA Katılım Kasım 2021
504 Takip Edilen383 Takipçiler
Daniela V. Castro retweetledi
George Zhang
George Zhang@ActuallyGZhang·
First ever #ASCOGU, and I feel so excited to have presented our analysis of RCC clinical trial availability in the U.S. As the treatment landscape advances, which populations are being represented? So much love to all of #TeamPal @cityofhope for their support ❤️ @ASCO #GU26
George Zhang tweet mediaGeorge Zhang tweet mediaGeorge Zhang tweet media
English
2
10
26
3.4K
Daniela V. Castro retweetledi
Miguel Zugman
Miguel Zugman@mzugman·
Thank you for the highlight, my friend! Please don’t miss a great session, covering many other biomarkers, including LAG3 and KIM-1 in ccRCC and PD-L1 expression in the context of the SUNNIFORECAST trial. @DrRanaMcKay @VincentWenxinXu @TiansterZhang
Salvador Jaime-Casas, MD@SalvadorjcMD

🎯 For those attending @myESMO #ESMO25 #esmo2025, be sure to join session 2610MO on October 19 at 9:10 AM! My colleague and friend, @mzugman, an exceptional postdoctoral fellow at @cityofhope @CityofHope_GU, will be presenting his study on the genomic landscape of papillary renal cell carcinoma (PRCC). 🧬 Don’t miss this exciting presentation showcasing cutting-edge insights into PRCC biology!

English
1
5
21
4.3K
Daniela V. Castro retweetledi
Hedyeh Ebrahimi
Hedyeh Ebrahimi@EbrahimiHedyeh·
Great overview by @_ShankarSiva at #ESMO25 on the role of SABR/SBRT in oligoprogressive RCC SABR is safe, non-invasive, and allows continuation of systemic therapy without interruption Ongoing trials are actively exploring its synergy with systemic therapy @urotoday @OncoAlert @yunroseli
Hedyeh Ebrahimi tweet mediaHedyeh Ebrahimi tweet mediaHedyeh Ebrahimi tweet mediaHedyeh Ebrahimi tweet media
English
0
13
35
2.6K
Daniela V. Castro retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
What a pleasure to work with @vabreugoes - a terrific scholar from @hosp_einstein. Impressive presentation at #ASCOQLTY25 - & so glad he connected w @PauloBergerot & @crisbergerot @oncoclinicas (fmr @cityofhope) as well!
Sumanta K. Pal, MD, FASCO tweet media
Vitor Abreu de Góes, MD@vabreugoes

Honored to present my poster at ASCO Quality Care Symposium 2025 in Chicago this week! It was a great opportunity to share our work on global disparities in clinical trial avaiability! I am truly grateful for the support of my mentors @montypal, @mzugman and @ReginaBarCar

English
0
8
31
5.4K
Daniela V. Castro retweetledi
Salvador Jaime-Casas, MD
Salvador Jaime-Casas, MD@SalvadorjcMD·
🚨 Thrilled to share our new manuscript in @Cancers_MDPI! 🚀 We evaluated clinical & pathologic predictors for pUS at cystectomy in pts with MIBC. Huge thanks to the team at @cityofhope @CityofHope_GU and to incredible mentors @AbhiTrip87 @montypal @WesleyYipMD @ClaytonLauMD 🙏 👥 Pts cT2-4N0M0 grouped: 1️⃣ pUS w/o NAC 2️⃣ pUS w/ NAC 3️⃣ No pUS 📊 277 pts; 38.6% (n=107) had pUS, 37 w/ NAC and 70 w/o NAC 💧 Preop hydronephrosis = higher odds of pUS [OR 2.24] ⬇️ pUS (w/ or w/o NAC) = worse OS & RFS vs no pUS 🏆 Strongest predictor for pUS at: Preop hydronephrosis 🔎 Takeaway: Need better pre-op risk assessment in MIBC! ⚠️ High-risk features like hydronephrosis should prompt closer evaluation due to pUS risk at cystectomy. mdpi.com/2072-6694/17/1…
Salvador Jaime-Casas, MD tweet media
English
0
6
17
3.4K
Daniela V. Castro retweetledi
Salvador Jaime-Casas, MD
Salvador Jaime-Casas, MD@SalvadorjcMD·
1/ JUST PUBLISHED at #CGC journal: Evaluating Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy 🔵Occult LN involvement occurs in 25% of pts with cN0 MIBC. 🔵LN involvement can significantly affect oncologic outcomes, with 5-yr OS rate of approx 32%, compared to 75% in pts without LN involvement. 🔵We leveraged our institutional database to determine clinical and pathological variables associated with pLN+ in patients with clinically node-negative BC (cN0) clinical-genitourinary-cancer.com/article/S1558-…
Salvador Jaime-Casas, MD tweet media
English
3
8
40
8.5K
Daniela V. Castro retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
Terrific conference that so many of my @cityofhope colleagues have benefitted from - @NazliDizman @AlexisLevee @DVCastro_ @ReginaBarCar @EbrahimiHedyeh - please consider attending!
Ana I. Velázquez Mañana, MD, MSc, FASCO@AnaVManana

🚨 Leadership isn’t built alone! Join us in Arizona for #LEAD2025 — a unique space to recharge, connect, and grow as leaders. Leadership building • Networking • Learning💡 ✨Focusing on YOU ✨ ➡️ Don’t miss it! 📅 September 26-27, 2025 📍Scottsdale, AZ Register: loom.ly/jylJ7Gc #WomenInOncology #WomenInHematology #WomenInMedicine @HemOncWomenDocs @WomenInLymphoma #Oncology @rachnatshroff @KatieLaiMD_MPH

English
0
6
20
2.9K
Daniela V. Castro retweetledi
Nick Salgia
Nick Salgia@NickSalgia·
Excited to share the bulk of my thesis work available online today @CancerCell. We sought to dive into the tumor microenvironment of sarcomatoid renal cell carcinomas to better understand what makes RCC tumors susceptible to immunotherapy: sciencedirect.com/science/articl… 1/n
English
5
24
109
16K
Daniela V. Castro retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
Proud of @ruchia_upenn, a @Penn undergraduate who spent her summers working with us at @cityofhope. Today she presented her work with @ReginaBarCar @incanMX on international #kidneycancer trial availability - so impressive!
Sumanta K. Pal, MD, FASCO tweet media
Cristiane D Bergerot, PhD, FASCO@crisbergerot

Wonderful presentation by @ruchia_upenn highlighting global disparities in clinical trial availability for RCC. A crucial reminder of the inequities that persist and the urgent need for more inclusive research efforts. #KCRS25

English
1
9
54
6.1K
Daniela V. Castro retweetledi
Hedyeh Ebrahimi
Hedyeh Ebrahimi@EbrahimiHedyeh·
🥗 Powerful diet-focused study at #ASCO25 presented by @SaraKCharMD from CALGB/SWOG 80702: 🔹 Proinflammatory diet linked to worse OS in stage III colon cancer 🔹 Best outcomes in patients with high physical activity and anti-inflammatory diet 🔹 NSAIDs didn’t alter the diet-survival link 🙌 Love seeing nutrition, microbiome, & exercise take the podium spotlight @ASCO! @OncoAlert
Hedyeh Ebrahimi tweet mediaHedyeh Ebrahimi tweet mediaHedyeh Ebrahimi tweet mediaHedyeh Ebrahimi tweet media
English
1
11
25
1.7K
Daniela V. Castro retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
Huge congrats to @NazliDizman @MDAndersonNews! Can affirm that all the below is true! So proud. #ASCO25
HemOnc Today@HemOncToday

The NextGen Disruptor Award, given in partnership w/ Healio Community, goes to @NazliDizman! Dr. Dizman is... 💚 a second-year fellow at MD Anderson Cancer Center 💚 a voice for international medical graduates 💚 contributing to renal cell carcinoma research Congratulations!

English
0
14
44
2.7K
Daniela V. Castro retweetledi
Hedyeh Ebrahimi
Hedyeh Ebrahimi@EbrahimiHedyeh·
🏔️ A standing ovation at #ASCO25 for Dr. Christopher Booth and the CHALLENGE (CO.21) trial. A 3-year structured exercise program post-chemo in stage II/III colon cancer: ✅ Improved OS (HR 0.63, p=0.022) ✅ 1 life saved for every 14 patients 💬 “Exercise is no longer just a QOL intervention - it is a treatment for colon cancer.” 📖 Simultaneously published in @NEJM today. #ColorectalCancer @CDNCancerTrials @ASCO @OncoAlert
Hedyeh Ebrahimi tweet mediaHedyeh Ebrahimi tweet mediaHedyeh Ebrahimi tweet mediaHedyeh Ebrahimi tweet media
English
1
15
30
7.9K
Daniela V. Castro retweetledi
Zeynep Zengin
Zeynep Zengin@ZeynepZengin·
#AACR25 In our study high baseline CD5 B cells linked to worse outcomes in mRCC patients treated with cabo/nivo. ➡️CD5+ B cells may be a prognostic biomarker—and potential target—for ICB response Thank you @montypal @kortylmt @EbrahimiHedyeh and @AlcantaraMarice!
Zeynep Zengin tweet mediaZeynep Zengin tweet media
English
1
13
48
3.4K
Daniela V. Castro retweetledi
Zeynep Zengin
Zeynep Zengin@ZeynepZengin·
It’s been a minute! Good morning Chicago ☀️ I will be at @AACR today presenting our work on CD5 cells and IO response. If you are interested in learning more, join me at Section 32/Board 26 (9-12AM PST). Appreciate the support of @montypal who made this possible and @kortylmt
Zeynep Zengin tweet media
English
1
14
90
8.4K
Daniela V. Castro retweetledi
Salvador Jaime-Casas, MD
Salvador Jaime-Casas, MD@SalvadorjcMD·
Incredible paper led by @DVCastro_ exploring the impact of insurance status on oncologic outcomes in pts with mRCC. @JCO_ASCO #OncologyAdvances
Daniela V. Castro@DVCastro_

🧵 1/7 Newly published @JCO_ASCO #OncologyAdvances! Our study explores how insurance status affects survival outcomes for patients with metastatic renal cell carcinoma (mRCC) receiving first-line systemic therapy. Read here: doi.org/10.1200/OA.24.…

English
0
3
18
2.6K

Keşfet

@cityofhope @ASCO @montypal @siadaneshmand @YuWeiChenMD @KidneyCancerDoc @WesleyYipMD @MOASC_Office